Puromycin Aminonucleoside | CAS#58-60-6 | ZO-1 modulator

MedKoo Cat#: 530551 | Name: Puromycin Aminonucleoside

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Puromycin Aminonucleoside, also known as PAN, NSC3056, is useful in the study of human glomerular disease, and glomerular function and morphology. PAN is used to probe endothelial glycosaminoglycan synthesis in cultured glomerular endothelial cells and their relation to cell permeability.PAN treatment increased oxidative stress level of podocytes significantly with the induction of Nox4. Puromycin aminonucleoside increases podocyte permeability by modulating ZO-1 in an oxidative stress-dependent manner.

Chemical Structure

Puromycin Aminonucleoside

CAS#58-60-6

Theoretical Analysis

MedKoo Cat#: 530551

Name: Puromycin Aminonucleoside

CAS#: 58-60-6

Chemical Formula: C12H18N6O3

Exact Mass: 294.1440

Molecular Weight: 294.32

Elemental Analysis: C, 48.97; H, 6.16; N, 28.56; O, 16.31

Price and Availability

Size	Price	Availability
50mg	USD 750.00	2 Weeks
100mg	USD 1,250.00	2 Weeks
200mg	USD 1,950.00	2 Weeks
500mg	USD 2,650.00	2 Weeks
1g	USD 3,850.00	2 Weeks
2g	USD 5,950.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Puromycin Aminonucleoside; ARDMA; NSC 3056; SAN; Stylomycin aminonucleoside.

IUPAC/Chemical Name

(2R,3R,4S,5S)-4-amino-2-(6-(dimethylamino)-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3-ol

InChi Key

RYSMHWILUNYBFW-GRIPGOBMSA-N

InChi Code

InChI=1S/C12H18N6O3/c1-17(2)10-8-11(15-4-14-10)18(5-16-8)12-9(20)7(13)6(3-19)21-12/h4-7,9,12,19-20H,3,13H2,1-2H3/t6-,7-,9-,12-/m1/s1

SMILES Code

O[C@H]([C@@H]1N)[C@@H](O[C@@H]1CO)N2C(N=CN=C3N(C)C)=C3N=C2

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO and water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Puromycin aminonucleoside (PAN)-induced nephrosis is a widely studied animal model of human idiopathic nephrotic syndrome because PAN injection into rats results in increased glomerular permeability with the characteristic ultrastructural changes in podocytes similar to human nephrosis.

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Puromycin inhibits protein synthesis by binding to RNA. It is an antineoplastic and antitrypanosomal agent and is used in research as an inhibitor of protein synthesis. It also serves an an anticancer drug by suppressing the growth and metastasis in esophagus cancer cells by Akt phosphorylation.

In vitro activity:

The effects of Puromycin aminonucleoside (PAN) were investigated on podocytes in the context of diabetic nephropathy. PAN treatment had a dose- and time-dependent inhibitory effect on podocyte proliferation, suggesting its role in suppressing cell growth. KLF5 overexpression induced cell cycle arrest in podocytes when regulated by PAN. KLF5 overexpression was shown to inhibit PAN-induced apoptosis of podocyte. Reference: Mol Med Rep. 2018 Oct;18(4):3843-3849. https://pubmed.ncbi.nlm.nih.gov/30106142/

In vivo activity:

In adult zebrafish, puromycin administration led to kidney injury, causing rapid clearance of substances from the kidney and resulting in morphological changes in the kidney structure, which recovered over time. During the process of nephron injury and regeneration, various molecular markers associated with kidney injury and repair showed significant changes, including increased expression of renal progenitor marker lhx1a and upregulation of NFκB, TNFα, Nampt, and p-ERK. Reference: Anim Cells Syst (Seoul). 2023 Apr 20;27(1):112-119. https://pubmed.ncbi.nlm.nih.gov/37089626/

	Solvent	mg/mL	mM
Solubility
	DMSO	25.0	84.94
	Water	40.0	135.91

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 294.32 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Li Y, Sui X, Hu X, Hu Z. Overexpression of KLF5 inhibits puromycin‑induced apoptosis of podocytes. Mol Med Rep. 2018 Oct;18(4):3843-3849. doi: 10.3892/mmr.2018.9366. Epub 2018 Aug 9. PMID: 30106142; PMCID: PMC6131625. 2. Hernández-Damián J, Tecalco-Cruz AC, Ríos-López DG, Vázquez-Victorio G, Vázquez-Macías A, Caligaris C, Sosa-Garrocho M, Flores-Pérez B, Romero-Avila M, Macías-Silva M. Downregulation of SnoN oncoprotein induced by antibiotics anisomycin and puromycin positively regulates transforming growth factor-β signals. Biochim Biophys Acta. 2013 Nov;1830(11):5049-58. doi: 10.1016/j.bbagen.2013.07.006. Epub 2013 Jul 18. PMID: 23872350. 3. Koun S, Park HJ, Jung SM, Cha JJ, Cha DR, Kang YS. Puromycin-induced kidney injury and subsequent regeneration in adult zebrafish. Anim Cells Syst (Seoul). 2023 Apr 20;27(1):112-119. doi: 10.1080/19768354.2023.2203211. PMID: 37089626; PMCID: PMC10120544. 4. Sakamoto H, Hirakawa Y, Ishida KI, Keeling PJ, Kita K, Matsuzaki M. Puromycin selection for stable transfectants of the oyster-infecting parasite Perkinsus marinus. Parasitol Int. 2019 Apr;69:13-16. doi: 10.1016/j.parint.2018.10.011. Epub 2018 Oct 30. PMID: 30389616.

In vitro protocol:

In vivo protocol:

1. Koun S, Park HJ, Jung SM, Cha JJ, Cha DR, Kang YS. Puromycin-induced kidney injury and subsequent regeneration in adult zebrafish. Anim Cells Syst (Seoul). 2023 Apr 20;27(1):112-119. doi: 10.1080/19768354.2023.2203211. PMID: 37089626; PMCID: PMC10120544. 2. Sakamoto H, Hirakawa Y, Ishida KI, Keeling PJ, Kita K, Matsuzaki M. Puromycin selection for stable transfectants of the oyster-infecting parasite Perkinsus marinus. Parasitol Int. 2019 Apr;69:13-16. doi: 10.1016/j.parint.2018.10.011. Epub 2018 Oct 30. PMID: 30389616.

1: Chen T, Shen XY, Liang HM, Shi H, Yuan L. Renal protective effects of helix B surface polypeptide in rats with puromycin aminonucleoside nephropathy. Ren Fail. 2024 Dec;46(2):2394637. doi: 10.1080/0886022X.2024.2394637. Epub 2024 Aug 27. PMID: 39189638; PMCID: PMC11351356. 2: Juncos LI, Adeoye AO, Martin FL, Juncos JP, Baigorria ST, García NH. Angiotensin II-independent abnormal renal vascular reactivity during puromycin nephropathy. J Med Life. 2024 Mar;17(3):309-313. doi: 10.25122/jml-2023-0367. PMID: 39044930; PMCID: PMC11262600. 3: Singh R, Jiang R, Williams J, Dobariya P, Hanak F, Xie J, Rothwell PE, Vince R, More SS. Modulation of endogenous opioid signaling by inhibitors of puromycin-sensitive aminopeptidase. Eur J Med Chem. 2024 Sep 5;275:116604. doi: 10.1016/j.ejmech.2024.116604. Epub 2024 Jun 17. PMID: 38917665; PMCID: PMC11236497. 4: Subramanian B, Williams S, Karp S, Hennino MF, Jacas S, Lee M, Riella CV, Alper SL, Higgs HN, Pollak MR. Missense Mutant Gain-of-Function Causes Inverted Formin 2 (INF2)-Related Focal Segmental Glomerulosclerosis (FSGS). bioRxiv [Preprint]. 2024 Jun 10:2024.06.08.598088. doi: 10.1101/2024.06.08.598088. PMID: 38915495; PMCID: PMC11195136. 5: Tang YW, Jiang MY, Cao JW, Wan F. Triptolide decreases podocytes permeability by regulating TET2-mediated hydroxymethylation of ZO-1. Exp Biol Med (Maywood). 2024 May 31;249:10051. doi: 10.3389/ebm.2024.10051. PMID: 38881848; PMCID: PMC11176508. 6: Yuan Y, Wu Y, He M, Jiang X. Astragaloside IV Protects Against Podocyte Injury by Upregulating Mitophagy via the Mfn2/Pink1/Parkin Axis. Curr Mol Med. 2024 Jun 11. doi: 10.2174/0115665240310818240531080353. Epub ahead of print. PMID: 38867537. 7: Singh R, Jiang R, Williams J, Dobariya P, Hanak F, Xie J, Rothwell PE, Vince R, More SS. Modulation of endogenous opioid signaling by inhibitors of puromycin sensitive aminopeptidase. bioRxiv [Preprint]. 2024 Apr 3:2024.04.02.587756. doi: 10.1101/2024.04.02.587756. Update in: Eur J Med Chem. 2024 Sep 5;275:116604. doi: 10.1016/j.ejmech.2024.116604. PMID: 38617237; PMCID: PMC11014559. 8: von Rauchhaupt E, Klaus M, Ribeiro A, Honarpisheh M, Li C, Liu M, Köhler P, Adamowicz K, Schmaderer C, Lindenmeyer M, Steiger S, Anders HJ, Lech M. GDF-15 Suppresses Puromycin Aminonucleoside-Induced Podocyte Injury by Reducing Endoplasmic Reticulum Stress and Glomerular Inflammation. Cells. 2024 Apr 5;13(7):637. doi: 10.3390/cells13070637. PMID: 38607075; PMCID: PMC11011265. 9: Szałapata K, Pięt M, Kasela M, Grąz M, Kapral-Piotrowska J, Mordzińska-Rak A, Samorek E, Pieniądz P, Polak J, Osińska-Jaroszuk M, Paduch R, Pawlikowska- Pawlęga B, Malm A, Jarosz-Wilkołazka A. Modified polymeric biomaterials with antimicrobial and immunomodulating properties. Sci Rep. 2024 Apr 5;14(1):8025. doi: 10.1038/s41598-024-58730-3. PMID: 38580807; PMCID: PMC10997598. 10: Waller AP, Wolfgang KJ, Pruner I, Stevenson ZS, Abdelghani E, Muralidharan K, Wilkie TK, Blissett AR, Calomeni EP, Vetter TA, Brodsky SV, Smoyer WE, Nieman MT, Kerlin BA. Prothrombin Knockdown Protects Podocytes and Reduces Proteinuria in Glomerular Disease. bioRxiv [Preprint]. 2024 Mar 2:2023.06.20.544360. doi: 10.1101/2023.06.20.544360. PMID: 38464017; PMCID: PMC10925217. 11: Wang MX, Luo KK, Gao WY, Tian MY, Zhao HY, Si N, Bian BL, Wei XL, Wang HJ, Zhou YY. [Study on biomarkers of acteoside in treating puromycin aminonucleoside nephropathy in young rats based on non-targeted urine metabolomics technology]. Zhongguo Zhong Yao Za Zhi. 2023 Nov;48(21):5898-5907. Chinese. doi: 10.19540/j.cnki.cjcmm.20230707.406. PMID: 38114186. 12: Wu D, Jiang T, Zhang S, Huang M, Zhu Y, Chen L, Zheng Y, Zhang D, Yu H, Yao G, Sun L. Blockade of Notch1 Signaling Alleviated Podocyte Injury in Lupus Nephritis Via Inhibition of NLRP3 Inflammasome Activation. Inflammation. 2024 Apr;47(2):649-663. doi: 10.1007/s10753-023-01935-x. Epub 2023 Dec 12. PMID: 38085465. 13: Stamellou E, Agrawal S, Siegerist F, Buse M, Kuppe C, Lange T, Buhl EM, Alam J, Strieder T, Boor P, Ostendorf T, Gröne HJ, Floege J, Smoyer WE, Endlich N, Moeller MJ. Inhibition of the glucocorticoid receptor attenuates proteinuric kidney diseases in multiple species. Nephrol Dial Transplant. 2024 Jun 28;39(7):1181-1193. doi: 10.1093/ndt/gfad254. PMID: 38037533; PMCID: PMC11210988. 14: Veissi ST, van den Berge T, van Wijk JAE, van der Velden T, Classens R, Lunsonga L, Brockotter R, Kaffa C, Bervoets S, Smeets B, van den Heuvel LPWJ, Schreuder MF. Levamisole Modulation of Podocytes' Actin Cytoskeleton in Nephrotic Syndrome. Biomedicines. 2023 Nov 13;11(11):3039. doi: 10.3390/biomedicines11113039. PMID: 38002039; PMCID: PMC10669662. 15: Zhang B, Huang S, Liu Z, Liu X, Jiang Z, Chen J, Zeng Y. Investigation of the Metabolism of Astragaloside IV in a Puromycin-Damaged Rat Model by UPLC-Q- TOF-MS/MS Analysis. Planta Med. 2024 Feb;90(2):154-165. doi: 10.1055/a-2186-3182. Epub 2023 Nov 6. PMID: 37931776. 16: Xu Z, Wang Y, Feng Y, Yang M, Shi G, Xuan Z, Xu F. Characteristics of sodium and water retention in rats with nephrotic syndrome induced by puromycin aminonucleoside. BMC Nephrol. 2023 Oct 25;24(1):309. doi: 10.1186/s12882-023-03367-z. PMID: 37880610; PMCID: PMC10599035. 17: Veloso Pereira BM, Zeng Y, Maggiore JC, Schweickart RA, Eng DG, Kaverina N, McKinzie SR, Chang A, Loretz CJ, Thieme K, Hukriede NA, Pippin JW, Wessely O, Shankland SJ. Podocyte injury at young age causes premature senescence and worsens glomerular aging. Am J Physiol Renal Physiol. 2024 Jan 1;326(1):F120-F134. doi: 10.1152/ajprenal.00261.2023. Epub 2023 Oct 19. PMID: 37855038; PMCID: PMC11198990. 18: Elshani M, Um IH, Leung S, Reynolds PA, Chapman A, Kudsy M, Harrison DJ. Transcription Factor NFE2L1 Decreases in Glomerulonephropathies after Podocyte Damage. Cells. 2023 Aug 29;12(17):2165. doi: 10.3390/cells12172165. PMID: 37681897; PMCID: PMC10487238. 19: Susa K, Kobayashi K, Galichon P, Matsumoto T, Tamura A, Hiratsuka K, Gupta NR, Yazdi IK, Bonventre JV, Morizane R. ATP/ADP biosensor organoids for drug nephrotoxicity assessment. Front Cell Dev Biol. 2023 Mar 2;11:1138504. doi: 10.3389/fcell.2023.1138504. PMID: 36936695; PMCID: PMC10017499. 20: Siregar RS, Ramayani OR, Haris D, Lelo A, Jusuf NK, Eyanoer PC, Rusda M, Amin MM. Comparison of Gambier Extract (Uncaria Gambier Robx) and Angiotensin Receptor Blocker on Proteinuria Reduction and Antioxidants - Enhancement in Nephrotic Rat Models. Med Arch. 2023;77(6):422-427. doi: 10.5455/medarh.2023.77.422-427. PMID: 38313113; PMCID: PMC10834053.